RAF1 and esophageal adenocarcinoma: Recent studies have shown that the first RAF inhibitor approved by the Food and Drug Administration (FDA), Sorafenib (SFB), inhibited cell proliferation that was stimulated by acid or bile acid treatments in esophageal adenocarcinoma by abrogating MAPK activation [10, 11].